1. South Korea Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Celltrion, Inc.

Celltrion, Inc.

KKRX:068270
194,400.00
KRW
+100.00
(+0.05%)
6,855.67EPS
25.26P/E
39.74TMarket Cap
Mar 03Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1,448.92
3,017.55
3,761.57
4,062.05
5,734.06
5,926.72
6,813.6
11,148.88
11,398.92
13,859.01
13,320.67
14,481.09
17,973.02
21,321.36
Basic EPS, GAAP
656.25
721.81
912.82
962.89
2,224.69
1,483.11
1,817.61
3,121.73
3,488.57
3,263.56
3,278.39
1,720.7
4,445.71
6,861.24
Free Cash Flow per Basic Share
319.69
62.59
-667.12
439.79
2,350.19
1,067.99
1,134.27
-1,149.46
3,549.56
-1,887.88
1,122.65
2,313.63
1,357.17
2,388.82
Dividend per Share
16.61
- -
- -
- -
- -
- -
- -
- -
0.02
621.67
316.2
421.75
663.93
- -
Book Value per Share
7,202.93
8,334.74
10,080.48
12,328.04
14,099.74
15,318.89
17,489.29
20,326.87
24,044.05
26,199.62
71,472.29
77,890.27
74,934.34
78,066.49
Tangible Book Value per Share
3,873.55
4,315.3
6,397.61
7,769.33
9,240.36
9,866.45
11,100.93
11,697.63
14,888.77
15,931.29
15,531.09
16,693.28
14,936.84
16,199.48
Basic Weighted Avg Shares
156
156
160
165
166
166
166
166
166
165
163
246
232
230
Sales/Revenue/Turnover
226,208
471,046
603,413
670,581
949,080
982,075
1,128,460
1,849,116
1,893,401
2,283,967
2,176,432
3,557,304
4,162,495
4,897,805
Operating Margin (%)
44.14
42.77
40.15
32.99
52.64
32.9
33.81
38.86
39.3
28.34
29.93
13.83
27.78
31.66
Depreciation Expense
47,710
76,279
81,599
84,774
97,950
124,826
153,720
173,850
214,160
226,390
245,827
418,250
287,528
293,321
Net Income, GAAP
102,455
112,676
146,430
158,958
368,222
245,755
301,030
517,760
579,465
537,836
535,648
422,692
1,029,613
1,576,119
Effective Tax Rate (%)
11.42
21.21
3
24.32
21.81
21.27
21.09
20
20.69
15.14
19.58
27.29
10.59
11.96
Profit Margin (%)
45.29
23.92
24.27
23.7
38.8
25.02
26.68
28
30.6
23.55
24.61
11.88
24.74
32.18
Working Capital
53,733
299,100
429,566
629,996
997,253
986,194
1,127,890
1,459,728
1,863,991
1,635,695
2,581,626
2,397,009
1,751,452
1,862,273
LT Debt
359,869
441,368
270,909
207,964
224,103
103,083
143,066
202,958
174,757
154,468
107,116
105,684
412,267
412,884
Total Equity
1,087,132
1,347,781
1,702,780
2,060,873
2,410,498
2,595,259
2,872,913
3,427,580
4,050,375
4,274,204
17,125,794
17,580,062
17,352,530
18,048,160
Return on Invested Capital (%)
5
7.82
9.9
6.27
13.18
8.1
9.15
14.85
12.68
10.8
4.32
1.83
5.08
6.57
Return on Capital (%)
7.51
6.85
7.91
6.94
12.78
8.62
9.54
13.63
12.66
10.94
4.48
2.48
5.36
8.04
Return on Common Equity (%)
9.59
9.65
10.24
8.93
17.39
10.3
11.48
17.07
16.04
13.35
5.07
2.46
5.94
9.16

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
3,316,402
3,436,647
3,453,854
LT Borrowings
387,200
387,200
387,200
LT Finance Leases
25,067
24,069
25,684
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
230
230
229
Market Capitalization
39,586,833
43,129,964
39,742,402

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
6,205,268
6,692,849
6,975,939
Cash, Cash Equivalents & STI
1,239,107
1,418,676
1,258,167
Accounts Receivable, Net
1,790,422
1,909,618
2,220,125
Inventories
2,803,460
2,863,640
2,940,521
Total Current Liabilities
4,453,816
4,816,507
5,113,666
Payables & Accruals
- -
- -
- -
ST Debt
3,316,402
3,436,647
3,453,854
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
40.14%
65.15%
-1.29%
Free Cash Flow
-53.77%
-111.17%
-44.7%
Net Income, GAAP
32.83%
25.36%
143.58%
Sales/Revenue/Turnover
23.37%
19.75%
17.01%
Total Cash Common Dividend
- -
- -
48.41%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
736,980
874,741
881,933
1,063,649
3,557,304
2025
841,912
961,457
1,028,969
1,330,157
4,162,495
2026
1,144,986
1,393,693
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
94.45
301.76
332.29
1,056.97
1,720.7
2025
445.97
250.48
1,438.62
2,302.07
4,445.71
2026
1,507.47
1,614
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
400.71
0.03
- -
421.75
2025
- -
- -
- -
- -
663.93
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Woo-Sung Kee
Full Time Employees
3,153
Sector
Health technology
Industry
Biotechnology
Address
23 Academy-ro Inchon IN South Korea 22014
IPO Date
Jul 19, 2005
Website
celltrion.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Celltrion, Inc. is a South Korean biopharmaceutical company primarily engaged in the development, manufacturing, and sale of biosimilar and innovative biopharmaceutical products. Its core product portfolio includes biosimilars of major biologic drugs such as Remsima (infliximab), Truxima (rituximab), and Herzuma (trastuzumab), which are used to treat autoimmune diseases and cancers. Additionally, Celltrion provides contract manufacturing services for monoclonal antibodies and other biopharmaceuticals. The company also offers novel drug candidates in various stages of development and operates across multiple geographic regions including Asia, Europe, and the Americas. Founded in 2002, Celltrion is headquartered in Incheon, South Korea. Recent significant developments for Celltrion include strategic alliances and expansions in its biosimilar portfolio, with ongoing launches and regulatory approvals to expand market presence globally. The company has actively pursued partnerships to enhance its R&D capabilities and expanded manufacturing capacity to support increasing demand. Within the last two years, Celltrion has introduced new biosimilar products and strengthened its global commercial footprint, reflecting a strategic focus on innovation and growth in the competitive biopharmaceutical industry. These operational expansions and product launches underscore its commitment to addressing unmet medical needs and supporting sustainable healthcare systems worldwide. Celltrion operates in the biopharmaceutical industry segment, targeting healthcare providers, hospitals, and patients requiring advanced biologic therapies. Its product offerings span biosimilar monoclonal antibodies and novel biologics, positioning the company as a key player in the global biosimilar market. The company also maintains several subsidiaries to support its manufacturing, R&D, and commercial activities worldwide, reinforcing its integrated business model from development to commercialization. Celltrion's headquarters in South Korea anchors its extensive operations distributed across global markets.